<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31776380</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Cromolyn sodium delays disease onset and is neuroprotective in the SOD1<sup>G93A</sup> Mouse Model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>17728</StartPage><MedlinePgn>17728</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17728</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-53982-w</ELocationID><Abstract><AbstractText>Accumulating evidence suggests that neuroinflammatory processes are implicated in the initiation and progression of amyotrophic lateral sclerosis (ALS). Previous reports have demonstrated an increase in microgliosis and astrogliosis in the lumbar spinal cord of SOD1<sup>G93A</sup> transgenic mice before the onset of symptoms, a neuroinflammatory response which correlated with disease progression. Importantly, early stage homeostatic microglia enhanced motor neuron survival, while pro-inflammatory microglia were toxic to motor neurons in the SOD1<sup>G93A</sup> mice. Recent studies from our group have demonstrated that cromolyn sodium, an FDA approved compound, exerts neuroprotective effects in mouse models of Alzheimer's disease by altering microglial cell activation. Here, we tested the neuroprotective and anti-inflammatory effects of cromolyn sodium in the SOD1<sup>G93A</sup> mouse model of ALS. Our results indicate that cromolyn sodium treatment significantly delayed the onset of neurological symptoms, and improved deficits in PaGE performance in both male and female mice, however, there was only an effect on survival in female mice. Furthermore, there was a significant increase in motor neuron survival in the lumbar spinal cord as well as a significant decrease in the denervation of the neuromuscular junction of the tibialis anterior muscle in cromolyn treated transgenic SOD1<sup>G93A</sup> mice. Lastly, cromolyn treatment decreased the expression of pro-inflammatory cytokines/chemokines in the lumbar spinal cord and plasma and decreased mast cell degranulation in the tibialis anterior muscle of transgenic SOD1<sup>G93A</sup> mice. Together, these findings suggest that cromolyn sodium provides neuroprotection in the SOD1<sup>G93A</sup> mice by decreasing the inflammatory response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Granucci</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griciuc</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Kaly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Alexandra N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Hoang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8427-3230</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dios</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGinty</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Joao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmaleh</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>AZTherapies, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spaulding Rehabilitation Hospital, Department of PM&amp;R, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadri-Vakili</LastName><ForeName>Ghazaleh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Healey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA. gsadrivakili@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q2WXR1I0PK</RegistryNumber><NameOfSubstance UI="D004205">Cromolyn Sodium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004205" MajorTopicYN="N">Cromolyn Sodium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>David Elmaleh is the Scientific Founder and Chairman of AZTherapies and provided cromolyn sodium for our studies. In addition, Rudolph Tanzi is the chairman of the Scientific Advisory Board at AZTherapies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31776380</ArticleId><ArticleId IdType="pmc">PMC6881366</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-53982-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-53982-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8:888&#x2013;899. doi: 10.1007/s11481-013-9489-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:364&#x2013;375. doi: 10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch EC, Hunot S. Neuroinflammation in Parkinson&#x2019;s disease: a target for neuroprotection? Lancet Neurol. 2009;8:382&#x2013;397. doi: 10.1016/S1474-4422(09)70062-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70062-6</ArticleId><ArticleId IdType="pubmed">19296921</ArticleId></ArticleIdList></Reference><Reference><Citation>Menza M, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson&#x2019;s disease. Psychosomatics. 2010;51:474&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987579</ArticleId><ArticleId IdType="pubmed">21051678</ArticleId></ArticleIdList></Reference><Reference><Citation>Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson&#x2019;s disease: focus on astrocytes. Mol Neurobiol. 2014;49:28&#x2013;38. doi: 10.1007/s12035-013-8483-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8483-x</ArticleId><ArticleId IdType="pubmed">23783559</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Siklos L, Appel SH. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci. 2006;31:427&#x2013;437. doi: 10.1016/j.mcn.2005.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.10.016</ArticleId><ArticleId IdType="pubmed">16337133</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2006;103:16021&#x2013;16026. doi: 10.1073/pnas.0607423103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607423103</ArticleId><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237:147&#x2013;152. doi: 10.1016/j.expneurol.2012.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori Y, et al. A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease. J Biol Chem. 2015;290:1966&#x2013;1978. doi: 10.1074/jbc.M114.586602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.586602</ArticleId><ArticleId IdType="pmc">PMC4303653</ArticleId><ArticleId IdType="pubmed">25468905</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, et al. Cromolyn Reduces Levels of the Alzheimer&#x2019;s Disease-Associated Amyloid beta-Protein by Promoting Microglial Phagocytosis. Sci Rep. 2018;8:1144. doi: 10.1038/s41598-018-19641-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19641-2</ArticleId><ArticleId IdType="pmc">PMC5773545</ArticleId><ArticleId IdType="pubmed">29348604</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyachandran A, Mertens B, McKissick EA, Mitchell CS. Type I Vs. Type II Cytokine Levels as a Function of SOD1 G93A Mouse Amyotrophic Lateral Sclerosis Disease Progression. Front Cell Neurosci. 2015;9:462. doi: 10.3389/fncel.2015.00462.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00462</ArticleId><ArticleId IdType="pmc">PMC4664727</ArticleId><ArticleId IdType="pubmed">26648846</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, et al. A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS. J Vis Exp. 2015;104:53257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitner M., Menzies S. &amp; Lutz C. Working with ALS mice: Guidelines for preclinical testing &amp; colony management. The Jackson Laboratory, http://jackson.jax.org/rs/444-BUH-304/images/Working_with_ALS_Mice.pdf (2009).</Citation></Reference><Reference><Citation>Fischer LR, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Glajch KE, et al. MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis. PLoS One. 2016;11:e0164103. doi: 10.1371/journal.pone.0164103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164103</ArticleId><ArticleId IdType="pmc">PMC5055348</ArticleId><ArticleId IdType="pubmed">27716798</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis KE, et al. Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase. J. Neuroscience. 2014;122:3063&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994340</ArticleId><ArticleId IdType="pubmed">24655927</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One. 2012;7:e39216. doi: 10.1371/journal.pone.0039216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039216</ArticleId><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, et al. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem. 2008;79:737&#x2013;746. doi: 10.1046/j.1471-4159.2001.00572.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00572.x</ArticleId><ArticleId IdType="pubmed">11723166</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron P, et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve. 2005;32:541&#x2013;4. doi: 10.1002/mus.20376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20376</ArticleId><ArticleId IdType="pubmed">15962273</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T, et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Res. 2007;29:772&#x2013;776. doi: 10.1179/016164107X229795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164107X229795</ArticleId><ArticleId IdType="pubmed">17672928</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Pharmacology. 2010;86:1&#x2013;5. doi: 10.1159/000314164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000314164</ArticleId><ArticleId IdType="pubmed">20559017</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med. 2015;373:1885&#x2013;1886. doi: 10.1056/NEJMra1409760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1409760</ArticleId><ArticleId IdType="pubmed">26535528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohman RJ, et al. Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nat Commun. 2017;8:351. doi: 10.1038/s41467-017-00414-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00414-w</ArticleId><ArticleId IdType="pmc">PMC5570900</ArticleId><ArticleId IdType="pubmed">28839129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A. et al. Mast cell stabilization alleviates acute lung injury after orthotopic autologous liver transplantation in rats by downregulating inflammation. PLoS One. 8, e75262 (2013).Han H. et al. Autophagy-linked FYVE protein (Alfy) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). In Vitro Cell Dev Biol Anim. 51, 249-63 (2015).</Citation></Reference><Reference><Citation>Han H, et al. Autophagy-linked FYVE protein (Alfy) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS) In Vitro Cell Dev Biol Anim. 2015;51:249&#x2013;63. doi: 10.1007/s11626-014-9832-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11626-014-9832-4</ArticleId><ArticleId IdType="pubmed">25385288</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;usler KG, et al. Interferon-gamma differentially modulates the release of cytokines and chemokines in lipopolysaccharide- and pneumococcal cell wall-stimulated mouse microglia and macrophages. Eur J Neurosci. 2002;16:2113&#x2013;2122. doi: 10.1046/j.1460-9568.2002.02287.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2002.02287.x</ArticleId><ArticleId IdType="pubmed">12473079</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011;147:742&#x2013;758. doi: 10.1016/j.cell.2011.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.10.033</ArticleId><ArticleId IdType="pmc">PMC4511103</ArticleId><ArticleId IdType="pubmed">22078876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, et al. Chemokines protect vascular smooth muscle cells from cell death induced by cyclic mechanical stretch. Sci Rep. 2017;7:16128. doi: 10.1038/s41598-017-15867-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-15867-8</ArticleId><ArticleId IdType="pmc">PMC5701048</ArticleId><ArticleId IdType="pubmed">29170451</ArticleId></ArticleIdList></Reference><Reference><Citation>Won YH, et al. Elucidation of Relevant Neuroinflammation Mechanisms Using Gene Expression Profiling in Patients with Amyotrophic Lateral Sclerosis. PLoS One. 2016;11:e0165290. doi: 10.1371/journal.pone.0165290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0165290</ArticleId><ArticleId IdType="pmc">PMC5094695</ArticleId><ArticleId IdType="pubmed">27812125</ArticleId></ArticleIdList></Reference><Reference><Citation>Welser-Alves JV, Milner R. Microglia are the major source of TNF-alpha and TGF-beta1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin. Neurochem Int. 2013;63:47&#x2013;53. doi: 10.1016/j.neuint.2013.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2013.04.007</ArticleId><ArticleId IdType="pmc">PMC3819935</ArticleId><ArticleId IdType="pubmed">23619393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa L, Caraballo-Miralles V, Olmos G, Llad&#xf3; J. TNF-alpha potentiates glutamate-induced spinal cord motoneuron death via NF-kappaB. Mol Cell Neurosci. 2011;46:176&#x2013;186. doi: 10.1016/j.mcn.2010.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2010.09.001</ArticleId><ArticleId IdType="pubmed">20849956</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin HZ, et al. TNF-&#x3b1; triggers rapid membrane insertion of Ca2+ permeable AMPA receptors into adult motor neurons and enhances their susceptibility to slow excitotoxic injury. Exp Neurol. 2012;238:93&#x2013;102. doi: 10.1016/j.expneurol.2012.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.08.004</ArticleId><ArticleId IdType="pmc">PMC3498614</ArticleId><ArticleId IdType="pubmed">22921461</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878&#x2013;888. doi: 10.1016/j.bbamcr.2011.01.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2011.01.034</ArticleId><ArticleId IdType="pubmed">21296109</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356:513&#x2013;519. doi: 10.1126/science.aal3535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3535</ArticleId><ArticleId IdType="pmc">PMC6260791</ArticleId><ArticleId IdType="pubmed">28473584</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2017;3:e123249. doi: 10.1172/jci.insight.123249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123249</ArticleId><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorospe JR, Nishikawa BK, Hoffman EP. Recruitment of mast cells to muscle after mild damage. J Neurol Sci. 1996;135:10&#x2013;17. doi: 10.1016/0022-510X(95)00255-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00255-Z</ArticleId><ArticleId IdType="pubmed">8926490</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves MC, et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:213&#x2013;219. doi: 10.1080/14660820410020286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410020286</ArticleId><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Glajch KE, Fleming SM, Surmeier DJ, Osten P. Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson&#x2019;s disease. Behav Brain Res. 2012;230:309&#x2013;316. doi: 10.1016/j.bbr.2011.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2011.12.007</ArticleId><ArticleId IdType="pmc">PMC3324279</ArticleId><ArticleId IdType="pubmed">22178078</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillerson JL, Caudle WM, Rever&#xf3;n ME, Miller GW. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol. 2002;178:80&#x2013;90. doi: 10.1006/exnr.2002.8021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2002.8021</ArticleId><ArticleId IdType="pubmed">12460610</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Hong SY, Kliot M, M&#xf6;ller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport. 2003;14:1051&#x2013;1054. doi: 10.1097/01.wnr.0000073685.00308.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wnr.0000073685.00308.89</ArticleId><ArticleId IdType="pubmed">12802201</ArticleId></ArticleIdList></Reference><Reference><Citation>Barn&#xe9;oud P, Lolivier J, Sanger DJ, Scatton B, Moser P. Quantitative motor assessment in FALS mice: a longitudinal study. Neuroreport. 1997;8:2861&#x2013;5. doi: 10.1097/00001756-199709080-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199709080-00012</ArticleId><ArticleId IdType="pubmed">9376520</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley, J. N. What&#x2019;s Wrong With My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice, 2nd Edition. 72&#x2013;73 (Wiley-Interscience, 2007).</Citation></Reference><Reference><Citation>Sango K, et al. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat Genet. 1996;14:348&#x2013;352. doi: 10.1038/ng1196-348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1196-348</ArticleId><ArticleId IdType="pubmed">8896570</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>